Vitanova Biomedical, Inc. (VNB)

Vitanova Biomedical, Inc. (VNB) is a San Antonio, TX-based early stage biotechnology company developing patented (pending) technology licensed from the University of Texas at San Antonio. The company’s cancer treatment, Light-Activated Intracellular Acidosis (LAIA), is based upon three accepted principles of cancer therapy: 1) Intracellular acidosis causes rapid pH-induced cancer cell death; 2) Compounds can be activated by specific wavelengths of light; and 3) Nanoparticles can be selectively targeted to specific cancer types using antibody-antigen conjugates. Our data support that LAIA effectively induces early cell apoptosis, resulting in 81-100% cancer cell death in less than two hours, across five different cancer cell types including triple negative breast, pancreatic and prostate cancer cells.